|
mGnP Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 3: 1
Top Sponsors
- Immuneering Corporation1
Indications
- PDAC1
- Pancreatic Adenocarcinoma Metastatic1
- Pancreatic Cancer Metastatic1
- PDAC - Pancreatic Ductal Adenocarcinoma1
- Pancreatic Ductal Adenocarcinoma (PDAC)1
New York, New York1 trial
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NYU Langone Health
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.